At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 122 enrolled
Drug / intervention
Nimotuzumab +2 moredrug
Likely dose
Nimotuzumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Randomized Phase Ⅱ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Nimotuzumab, docetaxel and cisplatin, and 1 other intervention for Non-small-cell Lung Cancer. Completed, enrolled 122 participants across 1 site.
Detailed Summary
This Phase II randomized study is to determine the efficacy and toxicity of Nimotuzumab in combined with chemoradiotherapy for unresectable,local advanced squamous cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small-cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedOct 2015
Primary CompletionJun 2020
Study CompletionOct 2020
TodayJul 2026
First PostedOct 16, 2015
Enrollment StartAug 1, 2015
Primary CompletionJun 1, 2020
Study CompletionOct 1, 2020
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 10.7 years ago
Interventions
Nimotuzumabdrug
Patients received weekly nimotuzumab (200mg, IV) concurrent with chemoradiotherapy.
docetaxel and cisplatindrug
Patients received weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
daily RT to the chestradiation
Patients received daily RT to the chest